German Biotech's $6.5M Seed Targets Heart Disease Breakthrough

Jan de Vries · 2026-08-28

Here's something that caught my eye this week—a German biotech startup just launched with serious backing and a mission to tackle some of the most stubborn heart conditions out there. Revier Therapeutics, based in Heidelberg, isn't just another lab with a theory. They've secured a $6.5 million seed round to put their science into action. That's about €6 million for our European readers, but we're talking straight USD here. That kind of early money tells you investors see real potential. The round was led by the KHAN Technology Transfer Fund II, with High-Tech Gründerfonds (HTGF), VORNvc, and private investors from Revier Invest Heidelberg all chipping in. It's a solid coalition betting on one thing: a new approach to cardiometabolic disease. ### The Problem They're Trying to Solve Let's talk about the human side for a second. Prof. Eva van Rooij, the company's CEO, put it plainly. Despite all our advances, millions of patients with specific heart failures and cardiovascular diseases still don't have great treatment options. The medicine exists, but it often manages symptoms rather than tackling the root cause. That's the gap Revier wants to fill. They're not looking for a band-aid; they're aiming for a cure that changes the disease itself. Their focus is on a class of enzymes called HDACs, specifically class IIa. Think of these like tiny switches inside your cells that can go wrong and drive disease. Earlier drugs tried to hit all the HDAC switches at once, which caused nasty side effects. Revier's approach is more like a precision lockpick. ### A More Precise Scientific Approach This is where it gets interesting. Their lead scientist, Prof. Johannes Backs, explains that their orally-available small molecules are designed to be selective. They aim to inhibit only the *bad* enzymatic activity that's causing the problem, while leaving the healthy, essential functions alone. It's a 'first-in-class' strategy, meaning nobody's done it quite this way for cardiometabolic diseases before. - **Target:** Class IIa HDAC enzymes, implicated in heart failure and atherosclerosis. - **Method:** Selective inhibition to avoid the side effects of broader HDAC drugs. - **Goal:** Develop disease-modifying therapies, not just symptom managers. The potential here is huge. Michael Hamacher from KHAN Technology Transfer Fund II called it a chance to "reshape the standard of care." That's investor-speak for: this could be a game-changer if it works. ### What's Next for the Startup? So, what does a biotech startup do with $6.5 million? It's all about advancing the pipeline. The capital will fuel their preclinical work on two main programs: one for heart failure with preserved ejection fraction (HFpEF) and another for atherosclerotic cardiovascular disease (ASCVD). They'll also be building out their team—adding operational, scientific, and clinical muscle to push toward human trials. It's a classic startup story, but with life-saving stakes. Deep science from a German university hub, a clear unmet medical need, and now, the fuel to run the first leg of the race. For professionals watching the European biotech scene, Revier Therapeutics is one to put on your radar. They're aiming not just to create a company, but to create a new category of treatment for millions of patients. And they've just gotten the green light to start building.